Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice

Journal of Drug Targeting

Volumn 19, Issue 8, 2011, Pages 701-708

  Hagtvet, Eirik ^a   Evjen, Tove J ^b,c   Olsen, Dag Rune ^d   Fossheim, Sigrid L ^b,e   Nilssen, Esben A ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Epitarget AS   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e Clavis Pharma ASA   (Norway)

Author keywords

Drug delivery; Drug release; Low frequency ultrasound; Therapeutic effect

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; ECHOGRAPHY; LOW FREQUENCY ULTRASOUND; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PHONOPHORESIS; PHOSPHATIDYLETHANOLAMINES; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959604381     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2010.551401     Document Type: Article

References (36)

1. Allen TM, Cleland LG. (1980). Serum-induced leakage of liposome contents. Biochim Biophys Acta, 597, 418-426. (Pubitemid 10066496)
2. Atchley AA, Frizzell LA, Apfel RE, Holland CK, Madanshetty S, Roy RA. (1988). Tresholds for cavitation produced in water by pulsed ultrasound. Ultrasonics, 26, 280-285.
3. Batist G. (2007). Cardiac safety of liposomal anthracyclines. Cardiovasc Toxicol, 7, 72-74. (Pubitemid 47339870)
4. Bonté F, Juliano RL. (1986). Interactions of liposomes with serum proteins. Chem Phys Lipids, 40, 359-372.
5. Charrois GJ, Allen TM. (2003). Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ter, 306, 1058-1067. (Pubitemid 37025314)
6. Cohen J, Cohen P, West SG, Aiken LS. (2003). Applied multiple regression/correlation analysis for the behavioral sciences (3rd ed.) Mahwah, NJ: Erlbaum.
7. Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, Zhang L, Hao Y, Wang Y. (2007). Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efcacy? J Control Release, 118, 204-215. (Pubitemid 46350710)
8. Davidsen J, Vermehren C, Frokjaer S, Mouritsen OG, Jørgensen K. (2001). Drug delivery by phospholipase A(2) degradable liposomes. Int J Pharm, 214, 67-69. (Pubitemid 32244080)
9. Deng CX, Xu Q, Apfel RE, Holland CK. (1996). In vitro measurements of inertial cavitation thresholds in human blood. Ultrasound Med Biol, 22, 939-948. (Pubitemid 26320204)
10. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev, 51, 691-743.
11. Dvorak J, Zoul Z, Melichar B, Petera J, Vesely P, Vosmik M, Dolezel M. (2004). Liposomal doxorubicin combined with regional hyperthermia: reducing systemic toxicity and improving locoregional efcacy in the treatment of solid tumors. J Chemother, 16 Suppl 5, 34-36. (Pubitemid 40052986)
12. Evjen TJ, Nilssen EA, Rögnvaldsson S, Brandl M, Fossheim SL. (2010). Dis tearoylphosphatidylethanolamine-based liposomes for ultrasound-mediated drug delivery. Eur J Pharm Biopharm, 75, 327-333.
13. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA. (2004). Cardiac safety of liposomal anthracyclines. Semin Oncol, 31, 161-181. (Pubitemid 40023246)
14. Favier J, Lapointe S, Maliba R, Sirois MG. (2007). HIF2 alpha reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma. BMC Cancer, 7, 139.
15. Frenkel V. (2008). Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev, 60, 1193-1208.
16. Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T. (1997). Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev, 24:337-44. (Pubitemid 27112652)
17. Gabizon A, Shiota R, Papahadjopoulos D. (1989). Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst, 81, 1484-1488. (Pubitemid 19252400)
18. Gabizon A, Shmeeda H, Barenholz Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet, 42, 419-436. (Pubitemid 36649037)
19. Huang SL, MacDonald RC. (2004). Acoustically active liposomes for drug encapsulation and ultrasound-triggered release. Biochim Biophys Acta, 1665, 134-141. (Pubitemid 39303578)
20. Jang SH, Wientjes MG, Lu D, Au JL. (2003). Drug delivery and transport to solid tumors. Pharm Res, 20, 1337-1350. (Pubitemid 37164040)
21. Lasic DD. (1993). Liposomes from Physics to Applications. Amsterdam: Elsevier Science Publishers B.V.
22. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. (2000). Tumor vascular permeability and the EPR efect in macromolecular therapeutics: a review. J Control Release, 65, 271-284. (Pubitemid 30122932)
23. Myhr G, Moan J. (2006). Synergistic and tumour selective efects of chemotherapy and ultrasound treatment. Cancer Lett, 232, 206-213. (Pubitemid 43170970)
24. Needham D, Dewhirst MW. (2001). Te development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev, 53, 285-305. (Pubitemid 34024911)
25. Ogawa R, Kondo T, Honda H, Zhao QL, Fukuda S, Riesz P. (2002). Efects of dissolved gases and an echo contrast agent on ultrasound mediated in vitro gene transfection. Ultrason Sonochem, 9, 197-203. (Pubitemid 34835668)
26. Pearson ES, Hartley HOE. (1976). Biometrika Tables for Statisticians (vol 1). Biometrica Trust, University College London.
27. Pitt WG, Husseini GA, Staples BJ. (2004). Ultrasonic drug delivery-a general review. Expert Opin Drug Deliv, 1, 37-56. (Pubitemid 40297955)
28. Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, Bodner DR, Jacobberger JW, Delmoro CM, Giaconia JM. (1993). Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst, 85, 394-398. (Pubitemid 23073158)
29. Schroeder A, Avnir Y, Weisman S, Najajreh Y, Gabizon A, Talmon Y, Kost J, Barenholz Y. (2007). Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. Langmuir, 23, 4019-4025. (Pubitemid 46581936)
30. Schroeder A, Honen R, Turjeman K, Gabizon A, Kost J, Barenholz Y. (2009a). Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release, 137, 63-68.
31. Schroeder A, Kost J, Barenholz Y. (2009b). Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes. Chem Phys Lipids, 162, 1-16.
32. Sudimack JJ, Guo W, Tjarks W, Lee RJ. (2002). A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta, 1564, 31-37. (Pubitemid 34717866)
33. Sundaram J, Mellein BR, Mitragotri S. (2003). An experimental and theoretical analysis of ultrasound-induced permeabilization of cell membranes. Biophys J, 84, 3087-3101. (Pubitemid 36531757)
34. Woodle MC, Collins LR, Sponsler E, Kossovsky N, Papahadjopoulos D, Martin FJ. (1992). Sterically stabilized liposomes. Reduction in electrophoretic mobility but not electrostatic surface potential. Biophys J, 61, 902-910.
35. Woodle MC, Newman MS, Cohen JA. (1994). Sterically stabilized liposomes: physical and biological properties. J Drug Target, 2, 397-403.
36. Working PK, Dayan AD. (1996). Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Hum Exp Toxicol, 15, 751-785. (Pubitemid 26331691)